Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRESSURE
NCT06575738Phase 1Recruiting
- Sponsor
- University of Colorado Denver
- Start
- Oct 2024
- Primary completion
- Sep 2027
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label trial of semaglutide and tirzepatide in obesity (3 arms), sponsored by University of Colorado Denver. Primary endpoints: Change in fasting glucagon-like peptide-1 at 6 months, Change in stimulated glucagon-like peptide-1 at 6 months and 6 more. Started Oct 2024; status: recruiting.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT06575738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06575738.